Rictor Is a Novel Regulator of TRAF6/TRAF3 in Osteoclasts
- PMID: 34155681
- DOI: 10.1002/jbmr.4398
Rictor Is a Novel Regulator of TRAF6/TRAF3 in Osteoclasts
Abstract
Tumor necrosis factor receptor-associated factors (TRAFs) are crucial for receptor activator of nuclear factor-κB (RANK) activation in osteoclasts. However, the upstream mechanisms of TRAF members in the osteoclastic lineage remain largely unknown. Here, we demonstrated that Rictor, a key component of mechanistic target of rapamycin complex 2 (mTORC2), was crucial for TRAF6/TRAF3 expression in osteoclasts. Our ex vivo and in vivo studies showed that Rictor ablation from the osteoclastic lineage reduced osteoclast numbers and increased bone mass in mice. Mechanistically, we found that Rictor ablation restricted osteoclast formation, which disrupted TRAF6 stability and caused autophagy block in a manner distinct from mTORC1, resulting in reduced TRAF3 degradation. Boosting TRAF6 expression or knockdown of TRAF3 levels in Rictor-deficient cells could both overcome the defect. Moreover, Rictor could interact with TRAF6 upon RANK ligand (RANKL) stimulation and loss of Rictor impaired TRAF6 stability and promoted its ubiquitinated degradation. These findings established an innovative link between Rictor, TRAF protein levels, and autophagic block. More importantly, mTOR complexes in the osteoclastic lineage are likely switches for coordinating TRAF6 and TRAF3 protein levels, and Rictor may function as an essential upstream regulator of TRAF6/TRAF3 that is partially independent of mTORC1 activity. Inhibitors targeting Rictor may therefore be valuable for preventing or treating osteoclast-related diseases. © 2021 American Society for Bone and Mineral Research (ASBMR).
Keywords: AUTOPHAGIC FLUX; OSTEOCLAST; RICTOR; TRAF3; TRAF6.
© 2021 American Society for Bone and Mineral Research (ASBMR).
Similar articles
-
RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors.J Biol Chem. 2017 Jun 16;292(24):10169-10179. doi: 10.1074/jbc.M116.771816. Epub 2017 Apr 24. J Biol Chem. 2017. PMID: 28438834 Free PMC article.
-
Bone Remodeling and the Role of TRAF3 in Osteoclastic Bone Resorption.Front Immunol. 2018 Sep 28;9:2263. doi: 10.3389/fimmu.2018.02263. eCollection 2018. Front Immunol. 2018. PMID: 30323820 Free PMC article. Review.
-
Tumor necrosis factor receptor-associated factor 6 is an intranuclear transcriptional coactivator in osteoclasts.J Biol Chem. 2008 Nov 7;283(45):30861-7. doi: 10.1074/jbc.M802525200. Epub 2008 Sep 3. J Biol Chem. 2008. PMID: 18768464 Free PMC article.
-
1α,25-(OH)2-D3 promotes the autophagy during osteoclastogenesis by enhancing RANKL-RANK-TRAF6 signaling.In Vitro Cell Dev Biol Anim. 2021 Oct;57(9):878-885. doi: 10.1007/s11626-021-00632-z. Epub 2021 Nov 15. In Vitro Cell Dev Biol Anim. 2021. PMID: 34780049
-
A tetravalent peptide that binds to the RANK-binding region of TRAF6 via a multivalent interaction efficiently inhibits osteoclast differentiation.Biochem Biophys Res Commun. 2022 Dec 25;636(Pt 1):178-183. doi: 10.1016/j.bbrc.2022.10.075. Epub 2022 Oct 25. Biochem Biophys Res Commun. 2022. PMID: 36334442
Cited by
-
Effects and mechanisms of natural alkaloids for prevention and treatment of osteoporosis.Front Pharmacol. 2022 Sep 23;13:1014173. doi: 10.3389/fphar.2022.1014173. eCollection 2022. Front Pharmacol. 2022. PMID: 36210805 Free PMC article. Review.
-
Vascular Pericyte-Derived Exosomes Inhibit Bone Resorption via Traf3.Int J Nanomedicine. 2023 Nov 28;18:7065-7077. doi: 10.2147/IJN.S438229. eCollection 2023. Int J Nanomedicine. 2023. PMID: 38046234 Free PMC article.
-
Diet X Gene Interactions Control Femoral Bone Adaptation to Low Dietary Calcium.JBMR Plus. 2022 Aug 19;6(9):e10668. doi: 10.1002/jbm4.10668. eCollection 2022 Sep. JBMR Plus. 2022. PMID: 36111202 Free PMC article.
-
Exploring the role and mechanism of Fuzi decoction in the treatment of osteoporosis by integrating network pharmacology and experimental verification.J Orthop Surg Res. 2023 Jul 18;18(1):508. doi: 10.1186/s13018-023-03842-1. J Orthop Surg Res. 2023. PMID: 37464262 Free PMC article.
-
Osteoclasts control endochondral ossification via regulating acetyl-CoA availability.Bone Res. 2024 Aug 28;12(1):49. doi: 10.1038/s41413-024-00360-6. Bone Res. 2024. PMID: 39198395 Free PMC article.
References
-
- Henriksen K, Bollerslev J, Everts V, Karsdal MA. Osteoclast activity and subtypes as a function of physiology and pathology-implications for future treatments of osteoporosis. Endocr Rev. 2011;32(1):31-63.
-
- Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337-342.
-
- Darnay BG, Besse A, Poblenz AT, Lamothe B, Jacoby JJ. TRAFs in RANK signaling. Adv Exp Med Biol. 2007;597:152-159.
-
- Lalani AI, Zhu S, Gokhale S, Jin J, Xie P. TRAF molecules in inflammation and inflammatory diseases. Curr Pharmacol Rep. 2018;4(1):64-90.
-
- Mukundan L, Bishop GA, Head KZ, Zhang L, Wahl LM, Suttles J. TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages. J Immunol. 2005;174(2):1081-1090.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous